ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Nationwide Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosis

21 окт 2022 07:00:00 Источник Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 окт 2022 15:00:00 Источник Nasdaq GlobeNewswire

Arcutis Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Scalp and Body Psoriasis

26 сен 2022 07:00:02 Источник Nasdaq GlobeNewswire

Journal of the American Medical Association Publishes Roflumilast Cream 0.3% Results from Pivotal DERMIS-1 and -2 Phase 3 Trials in Plaque Psoriasis

20 сен 2022 10:07:40 Источник Nasdaq GlobeNewswire

New Data from Arcutis’ STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis Presented at European Academy of Dermatology and Venereology (EADV) Congress

09 сен 2022 07:15:00 Источник Nasdaq GlobeNewswire

Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.

07 сен 2022 16:00:00 Источник Nasdaq GlobeNewswire

New Data from Arcutis’ Topical Roflumilast Clinical Program Presented at the European Academy of Dermatology and Venereology (EADV) Congress

06 сен 2022 07:00:02 Источник Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 сен 2022 15:00:00 Источник Nasdaq GlobeNewswire

Arcutis Announces Appointment of Neha Krishnamohan to Board of Directors

02 сен 2022 07:00:00 Источник Nasdaq GlobeNewswire

Arcutis to Present at Upcoming Investor Conference

01 сен 2022 07:00:01 Источник Nasdaq GlobeNewswire

Arcutis Completes Enrollment in INTEGUMENT-2 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis

23 авг 2022 07:00:01 Источник Nasdaq GlobeNewswire

Arcutis Announces Arcutis Cares™ Patient Assistance Program (PAP) For Financially Qualified Uninsured and Underinsured Patients

22 авг 2022 07:00:00 Источник Nasdaq GlobeNewswire

Arcutis Launches ZORYVE™ (Roflumilast) Cream 0.3% in the United States for Treatment of Plaque Psoriasis in Individuals Age 12 and Older

10 авг 2022 08:00:01 Источник Nasdaq GlobeNewswire

Arcutis Announces Second Quarter 2022 Financial Results and Provides Business Update

04 авг 2022 15:01:00 Источник Nasdaq GlobeNewswire

Arcutis Completes Enrollment in INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis

04 авг 2022 07:00:02 Источник Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 авг 2022 16:55:54 Источник Nasdaq GlobeNewswire

Arcutis Biotherapeutics Announces Pricing of Public Offering of Common Stock

02 авг 2022 20:26:57 Источник Nasdaq GlobeNewswire

Arcutis Biotherapeutics Announces Proposed Public Offering of Common Stock

02 авг 2022 15:02:00 Источник Nasdaq GlobeNewswire

FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older

29 июл 2022 15:05:00 Источник Nasdaq GlobeNewswire

Arcutis Biotherapeutics Announces Health Canada Accepts for Review the New Drug Submission for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis

11 июл 2022 07:00:01 Источник Nasdaq GlobeNewswire